ITI共识组1报告:种植体长度、设计及药物对临床与患者报告结局的影响
本文为ITI共识组1报告,基于四项系统评价,探讨短种植体、窄直径种植体、锥形设计及药物对种植牙临床与患者报告结局的影响,并形成共识声明与临床推荐。
要点
- 短种植体(≤6 mm)在骨高度不足时可避免增骨术相关并发症,但生存率变异性更高。
- 直径≥2.5 mm的窄种植体与标准直径种植体生存率无差异,<2.5 mm者生存率较低。
- 锥形与非锥形种植体在临床、影像及患者报告结局上无显著差异。
核心结论
- 短种植体(≤6 mm)在骨高度不足时是避免增骨术相关并发症的可行选择,但生存率变异性更高、可预测性较低。
- 直径≥2.5 mm的窄直径种植体与标准直径种植体生存率无差异,而直径<2.5 mm的窄直径种植体生存率较低。
- 锥形与非锥形种植体之间无差异。
- 某些选择性5-羟色胺再摄取抑制剂和质子泵抑制剂与种植失败率升高相关。
研究设计与样本
- ITI共识组1基于四项预先准备的系统评价,经结构化小组讨论达成共识,形成共识声明、临床推荐及未来研究建议,并提交全体会议讨论修改后接受。
主要发现
- 短种植体(≤6 mm)生存率为86.7%至100%,标准种植体为95%至100%,随访1至5年;短种植体失败风险比RR为1.24(95%CI:0.63,2.44,p=0.54)。
- 窄直径种植体分类:1类<2.5 mm,2类2.5至<3.3 mm,3类3.3至3.5 mm;平均生存率分别为94.7±5%、97.3±5%、97.7±2.3%。
- 锥形与非锥形种植体在临床、影像及患者报告结局上仅显示不显著差异。
- 某些选择性5-羟色胺再摄取抑制剂和质子泵抑制剂摄入与种植失败率显著升高相关;治疗骨质疏松的双膦酸盐摄入与种植失败率升高无关。
关键数值与推荐
- 短种植体(≤6 mm)适用于骨高度不足以避免增骨术相关并发症,但需注意生存率变异性更高。
- 直径≥2.5 mm的窄直径种植体与标准直径种植体生存率无差异。
- 直径<2.5 mm的窄直径种植体生存率低于标准直径种植体。
- 锥形与非锥形种植体之间无差异。
- 选择性5-羟色胺再摄取抑制剂和质子泵抑制剂与种植失败率升高相关,双膦酸盐(治疗骨质疏松)不增加失败率。
临床怎么用
- 骨高度不足时,短种植体(≤6 mm)可作为避免增骨术的选项,但应告知患者生存率变异性较高。
- 选择窄直径种植体时,直径≥2.5 mm者与标准直径生存率无差异,<2.5 mm者需谨慎评估风险。
- 锥形与非锥形种植体选择不影响临床、影像及患者报告结局。
- 种植术前应评估患者是否服用选择性5-羟色胺再摄取抑制剂或质子泵抑制剂,并告知相关失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of Working Group 1 was to address the influence of different local (implant length, diameter, and design) and systemic (medications) factors on clinical, radiographic, and patient-reported outcomes in implant dentistry. Focused questions on (a) short posterior dental implants (≤6 mm), (b) narrow diameter implants, (c) implant design (tapered compared to a non-tapered implant design), and (d) medication-related dental implant failures were addressed. MATERIALS AND METHODS: Four systematic reviews were prepared in advance of the Consensus Conference and were discussed among the participants of Group 1. Consensus statements, clinical recommendations, and recommendations for future research were based on structured group discussions until consensus was reached among the entire expert Group 1. The statements were then presented and accepted following further discussion and modifications as required by the plenary. RESULTS: Short implants (≤6 mm) revealed a survival rate ranging from 86.7% to 100%, whereas standard implant survival rate ranged from 95% to 100% with a follow-up from 1 to 5 years. Short implants demonstrated a higher variability and a higher Risk Ratio [RR: 1.24 (95% CI: 0.63, 2.44, p = 0.54)] for failure compared to standard implants. Narrow diameter implants (NDI) have been classified into three categories: Category 1: Implants with a diameter of <2.5 mm ("Mini-implants"); Category 2: Implants with a diameter of 2.5 mm to <3.3 mm; Category 3: Implants with a diameter of 3.3 mm to 3.5 mm. Mean survival rates were 94.7 ± 5%, 97.3 ± 5% and 97.7 ± 2.3% for category 1, 2 and 3. Tapered versus non-tapered implants demonstrated only insignificant differences regarding clinical, radiographic, and patient-reported outcomes. The intake of certain selective serotonin reuptake inhibitors and proton pump inhibitors is associated with a statistically significant increased implant failure rate. The intake of bisphosphonates related to the treatment of osteoporosis was not associated with an increased implant failure rate. CONCLUSIONS: It is concluded that short implants (≤6 mm) are a valid option in situations of reduced bone height to avoid possible morbidity associated with augmentation procedures; however, they reveal a higher variability and lower predictability in survival rates. Narrow diameter implants with diameters of 2.5 mm and more demonstrated no difference in implant survival rates compared to standard diameter implants. In contrast, it is concluded that narrow diameter implants with diameters of less than 2.5 mm exhibited lower survival rates compared to standard diameter implants. It is further concluded that there are no differences between tapered versus non-tapered dental implants. Certain medications such as selective serotonin reuptake inhibitors and proton pump inhibitors showed an association with a higher implant failure rate.
引用
- Jung RE, Al-Nawas B, Araujo M, et al. Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes. Clin Oral Implants Res. 2018. PMID: 30328189. doi:10.1111/clr.13342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。